According to our latest study, the global Patient-derived Xenograft (PDX) Models market size was valued at USD 341.2 million in 2022 and is forecast to a readjusted size of USD 591.4 million by 2029 with a CAGR of 8.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
This report is a detailed and comprehensive analysis for global Patient-derived Xenograft (PDX) Models market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Patient-derived Xenograft (PDX) Models market size and forecasts, in consumption value ($ Million), 2018-2029
Global Patient-derived Xenograft (PDX) Models market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Patient-derived Xenograft (PDX) Models market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Patient-derived Xenograft (PDX) Models market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Patient-derived Xenograft (PDX) Models
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Patient-derived Xenograft (PDX) Models market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Crown Bioscience, Champions Oncology, Wuxi Apptec, The Jackson Laboratory and EPO Berlin-Buch, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Patient-derived Xenograft (PDX) Models market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Mouse Model
Rat Model
Market segment by Application
Preclinical Drug development
Biomarker Analysis
Market segment by players, this report covers
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Patient-derived Xenograft (PDX) Models product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Patient-derived Xenograft (PDX) Models, with revenue, gross margin and global market share of Patient-derived Xenograft (PDX) Models from 2018 to 2023.
Chapter 3, the Patient-derived Xenograft (PDX) Models competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Patient-derived Xenograft (PDX) Models market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Patient-derived Xenograft (PDX) Models.
Chapter 13, to describe Patient-derived Xenograft (PDX) Models research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Patient-derived Xenograft (PDX) Models
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Patient-derived Xenograft (PDX) Models by Type
1.3.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type in 2022
1.3.3 Mouse Model
1.3.4 Rat Model
1.4 Global Patient-derived Xenograft (PDX) Models Market by Application
1.4.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Preclinical Drug development
1.4.3 Biomarker Analysis
1.5 Global Patient-derived Xenograft (PDX) Models Market Size & Forecast
1.6 Global Patient-derived Xenograft (PDX) Models Market Size and Forecast by Region
1.6.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Patient-derived Xenograft (PDX) Models Market Size by Region, (2018-2029)
1.6.3 North America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2018-2029)
1.6.4 Europe Patient-derived Xenograft (PDX) Models Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size and Prospect (2018-2029)
1.6.6 South America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Patient-derived Xenograft (PDX) Models Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Crown Bioscience
2.1.1 Crown Bioscience Details
2.1.2 Crown Bioscience Major Business
2.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Product and Solutions
2.1.4 Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Crown Bioscience Recent Developments and Future Plans
2.2 Champions Oncology
2.2.1 Champions Oncology Details
2.2.2 Champions Oncology Major Business
2.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Product and Solutions
2.2.4 Champions Oncology Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Champions Oncology Recent Developments and Future Plans
2.3 Wuxi Apptec
2.3.1 Wuxi Apptec Details
2.3.2 Wuxi Apptec Major Business
2.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Product and Solutions
2.3.4 Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Wuxi Apptec Recent Developments and Future Plans
2.4 The Jackson Laboratory
2.4.1 The Jackson Laboratory Details
2.4.2 The Jackson Laboratory Major Business
2.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product and Solutions
2.4.4 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 The Jackson Laboratory Recent Developments and Future Plans
2.5 EPO Berlin-Buch
2.5.1 EPO Berlin-Buch Details
2.5.2 EPO Berlin-Buch Major Business
2.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product and Solutions
2.5.4 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 EPO Berlin-Buch Recent Developments and Future Plans
2.6 Oncodesign
2.6.1 Oncodesign Details
2.6.2 Oncodesign Major Business
2.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Product and Solutions
2.6.4 Oncodesign Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Oncodesign Recent Developments and Future Plans
2.7 Xentech
2.7.1 Xentech Details
2.7.2 Xentech Major Business
2.7.3 Xentech Patient-derived Xenograft (PDX) Models Product and Solutions
2.7.4 Xentech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Xentech Recent Developments and Future Plans
2.8 Envigo
2.8.1 Envigo Details
2.8.2 Envigo Major Business
2.8.3 Envigo Patient-derived Xenograft (PDX) Models Product and Solutions
2.8.4 Envigo Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Envigo Recent Developments and Future Plans
2.9 Charles River Laboratories
2.9.1 Charles River Laboratories Details
2.9.2 Charles River Laboratories Major Business
2.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Product and Solutions
2.9.4 Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Charles River Laboratories Recent Developments and Future Plans
2.10 Pharmatest Services
2.10.1 Pharmatest Services Details
2.10.2 Pharmatest Services Major Business
2.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Product and Solutions
2.10.4 Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pharmatest Services Recent Developments and Future Plans
2.11 Urosphere
2.11.1 Urosphere Details
2.11.2 Urosphere Major Business
2.11.3 Urosphere Patient-derived Xenograft (PDX) Models Product and Solutions
2.11.4 Urosphere Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Urosphere Recent Developments and Future Plans
2.12 MEDICILON
2.12.1 MEDICILON Details
2.12.2 MEDICILON Major Business
2.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Product and Solutions
2.12.4 MEDICILON Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 MEDICILON Recent Developments and Future Plans
2.13 Horizon Discovery
2.13.1 Horizon Discovery Details
2.13.2 Horizon Discovery Major Business
2.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Product and Solutions
2.13.4 Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Horizon Discovery Recent Developments and Future Plans
2.14 Shanghai Model Organisms Center
2.14.1 Shanghai Model Organisms Center Details
2.14.2 Shanghai Model Organisms Center Major Business
2.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product and Solutions
2.14.4 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Shanghai Model Organisms Center Recent Developments and Future Plans
2.15 GemPharmatech
2.15.1 GemPharmatech Details
2.15.2 GemPharmatech Major Business
2.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Product and Solutions
2.15.4 GemPharmatech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 GemPharmatech Recent Developments and Future Plans
2.16 LIDE Biotech
2.16.1 LIDE Biotech Details
2.16.2 LIDE Biotech Major Business
2.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Product and Solutions
2.16.4 LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 LIDE Biotech Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Patient-derived Xenograft (PDX) Models Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Patient-derived Xenograft (PDX) Models by Company Revenue
3.2.2 Top 3 Patient-derived Xenograft (PDX) Models Players Market Share in 2022
3.2.3 Top 6 Patient-derived Xenograft (PDX) Models Players Market Share in 2022
3.3 Patient-derived Xenograft (PDX) Models Market: Overall Company Footprint Analysis
3.3.1 Patient-derived Xenograft (PDX) Models Market: Region Footprint
3.3.2 Patient-derived Xenograft (PDX) Models Market: Company Product Type Footprint
3.3.3 Patient-derived Xenograft (PDX) Models Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Patient-derived Xenograft (PDX) Models Consumption Value and Market Share by Type (2018-2023)
4.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2023)
5.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Application (2024-2029)
6 North America
6.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2029)
6.2 North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2029)
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country
6.3.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2029)
6.3.2 United States Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
6.3.3 Canada Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
6.3.4 Mexico Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2029)
7.2 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2029)
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country
7.3.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2029)
7.3.2 Germany Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
7.3.3 France Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
7.3.5 Russia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
7.3.6 Italy Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region
8.3.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2018-2029)
8.3.2 China Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8.3.3 Japan Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8.3.4 South Korea Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8.3.5 India Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
8.3.7 Australia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
9 South America
9.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2029)
9.2 South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2029)
9.3 South America Patient-derived Xenograft (PDX) Models Market Size by Country
9.3.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2029)
9.3.2 Brazil Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
9.3.3 Argentina Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country
10.3.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2029)
10.3.2 Turkey Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
10.3.4 UAE Patient-derived Xenograft (PDX) Models Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Patient-derived Xenograft (PDX) Models Market Drivers
11.2 Patient-derived Xenograft (PDX) Models Market Restraints
11.3 Patient-derived Xenograft (PDX) Models Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Patient-derived Xenograft (PDX) Models Industry Chain
12.2 Patient-derived Xenograft (PDX) Models Upstream Analysis
12.3 Patient-derived Xenograft (PDX) Models Midstream Analysis
12.4 Patient-derived Xenograft (PDX) Models Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Patient-derived Xenograft (PDX) Models Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Patient-derived Xenograft (PDX) Models Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Patient-derived Xenograft (PDX) Models Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Crown Bioscience Company Information, Head Office, and Major Competitors
Table 6. Crown Bioscience Major Business
Table 7. Crown Bioscience Patient-derived Xenograft (PDX) Models Product and Solutions
Table 8. Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Crown Bioscience Recent Developments and Future Plans
Table 10. Champions Oncology Company Information, Head Office, and Major Competitors
Table 11. Champions Oncology Major Business
Table 12. Champions Oncology Patient-derived Xenograft (PDX) Models Product and Solutions
Table 13. Champions Oncology Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Champions Oncology Recent Developments and Future Plans
Table 15. Wuxi Apptec Company Information, Head Office, and Major Competitors
Table 16. Wuxi Apptec Major Business
Table 17. Wuxi Apptec Patient-derived Xenograft (PDX) Models Product and Solutions
Table 18. Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Wuxi Apptec Recent Developments and Future Plans
Table 20. The Jackson Laboratory Company Information, Head Office, and Major Competitors
Table 21. The Jackson Laboratory Major Business
Table 22. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product and Solutions
Table 23. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. The Jackson Laboratory Recent Developments and Future Plans
Table 25. EPO Berlin-Buch Company Information, Head Office, and Major Competitors
Table 26. EPO Berlin-Buch Major Business
Table 27. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product and Solutions
Table 28. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. EPO Berlin-Buch Recent Developments and Future Plans
Table 30. Oncodesign Company Information, Head Office, and Major Competitors
Table 31. Oncodesign Major Business
Table 32. Oncodesign Patient-derived Xenograft (PDX) Models Product and Solutions
Table 33. Oncodesign Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Oncodesign Recent Developments and Future Plans
Table 35. Xentech Company Information, Head Office, and Major Competitors
Table 36. Xentech Major Business
Table 37. Xentech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 38. Xentech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Xentech Recent Developments and Future Plans
Table 40. Envigo Company Information, Head Office, and Major Competitors
Table 41. Envigo Major Business
Table 42. Envigo Patient-derived Xenograft (PDX) Models Product and Solutions
Table 43. Envigo Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Envigo Recent Developments and Future Plans
Table 45. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 46. Charles River Laboratories Major Business
Table 47. Charles River Laboratories Patient-derived Xenograft (PDX) Models Product and Solutions
Table 48. Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Charles River Laboratories Recent Developments and Future Plans
Table 50. Pharmatest Services Company Information, Head Office, and Major Competitors
Table 51. Pharmatest Services Major Business
Table 52. Pharmatest Services Patient-derived Xenograft (PDX) Models Product and Solutions
Table 53. Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Pharmatest Services Recent Developments and Future Plans
Table 55. Urosphere Company Information, Head Office, and Major Competitors
Table 56. Urosphere Major Business
Table 57. Urosphere Patient-derived Xenograft (PDX) Models Product and Solutions
Table 58. Urosphere Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Urosphere Recent Developments and Future Plans
Table 60. MEDICILON Company Information, Head Office, and Major Competitors
Table 61. MEDICILON Major Business
Table 62. MEDICILON Patient-derived Xenograft (PDX) Models Product and Solutions
Table 63. MEDICILON Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. MEDICILON Recent Developments and Future Plans
Table 65. Horizon Discovery Company Information, Head Office, and Major Competitors
Table 66. Horizon Discovery Major Business
Table 67. Horizon Discovery Patient-derived Xenograft (PDX) Models Product and Solutions
Table 68. Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Horizon Discovery Recent Developments and Future Plans
Table 70. Shanghai Model Organisms Center Company Information, Head Office, and Major Competitors
Table 71. Shanghai Model Organisms Center Major Business
Table 72. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product and Solutions
Table 73. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Shanghai Model Organisms Center Recent Developments and Future Plans
Table 75. GemPharmatech Company Information, Head Office, and Major Competitors
Table 76. GemPharmatech Major Business
Table 77. GemPharmatech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 78. GemPharmatech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. GemPharmatech Recent Developments and Future Plans
Table 80. LIDE Biotech Company Information, Head Office, and Major Competitors
Table 81. LIDE Biotech Major Business
Table 82. LIDE Biotech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 83. LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. LIDE Biotech Recent Developments and Future Plans
Table 85. Global Patient-derived Xenograft (PDX) Models Revenue (USD Million) by Players (2018-2023)
Table 86. Global Patient-derived Xenograft (PDX) Models Revenue Share by Players (2018-2023)
Table 87. Breakdown of Patient-derived Xenograft (PDX) Models by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Patient-derived Xenograft (PDX) Models, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 89. Head Office of Key Patient-derived Xenograft (PDX) Models Players
Table 90. Patient-derived Xenograft (PDX) Models Market: Company Product Type Footprint
Table 91. Patient-derived Xenograft (PDX) Models Market: Company Product Application Footprint
Table 92. Patient-derived Xenograft (PDX) Models New Market Entrants and Barriers to Market Entry
Table 93. Patient-derived Xenograft (PDX) Models Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Patient-derived Xenograft (PDX) Models Consumption Value (USD Million) by Type (2018-2023)
Table 95. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Type (2018-2023)
Table 96. Global Patient-derived Xenograft (PDX) Models Consumption Value Forecast by Type (2024-2029)
Table 97. Global Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023)
Table 98. Global Patient-derived Xenograft (PDX) Models Consumption Value Forecast by Application (2024-2029)
Table 99. North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2023) & (USD Million)
Table 100. North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2024-2029) & (USD Million)
Table 101. North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023) & (USD Million)
Table 102. North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2024-2029) & (USD Million)
Table 103. North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2023) & (USD Million)
Table 104. North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2024-2029) & (USD Million)
Table 105. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023) & (USD Million)
Table 108. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2024-2029) & (USD Million)
Table 109. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2023) & (USD Million)
Table 112. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2024-2029) & (USD Million)
Table 113. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023) & (USD Million)
Table 114. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2024-2029) & (USD Million)
Table 115. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2018-2023) & (USD Million)
Table 116. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2024-2029) & (USD Million)
Table 117. South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2023) & (USD Million)
Table 118. South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2024-2029) & (USD Million)
Table 119. South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023) & (USD Million)
Table 120. South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2024-2029) & (USD Million)
Table 121. South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2023) & (USD Million)
Table 122. South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2018-2023) & (USD Million)
Table 124. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2024-2029) & (USD Million)
Table 125. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2018-2023) & (USD Million)
Table 126. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2024-2029) & (USD Million)
Table 127. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2018-2023) & (USD Million)
Table 128. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2024-2029) & (USD Million)
Table 129. Patient-derived Xenograft (PDX) Models Raw Material
Table 130. Key Suppliers of Patient-derived Xenograft (PDX) Models Raw Materials
List of Figures
Figure 1. Patient-derived Xenograft (PDX) Models Picture
Figure 2. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type in 2022
Figure 4. Mouse Model
Figure 5. Rat Model
Figure 6. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application in 2022
Figure 8. Preclinical Drug development Picture
Figure 9. Biomarker Analysis Picture
Figure 10. Global Patient-derived Xenograft (PDX) Models Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Patient-derived Xenograft (PDX) Models Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Patient-derived Xenograft (PDX) Models Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region in 2022
Figure 15. North America Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Patient-derived Xenograft (PDX) Models Revenue Share by Players in 2022
Figure 21. Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Patient-derived Xenograft (PDX) Models Market Share in 2022
Figure 23. Global Top 6 Players Patient-derived Xenograft (PDX) Models Market Share in 2022
Figure 24. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Type (2018-2023)
Figure 25. Global Patient-derived Xenograft (PDX) Models Market Share Forecast by Type (2024-2029)
Figure 26. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Application (2018-2023)
Figure 27. Global Patient-derived Xenograft (PDX) Models Market Share Forecast by Application (2024-2029)
Figure 28. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 38. France Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region (2018-2029)
Figure 45. China Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 48. India Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Patient-derived Xenograft (PDX) Models Consumption Value (2018-2029) & (USD Million)
Figure 62. Patient-derived Xenograft (PDX) Models Market Drivers
Figure 63. Patient-derived Xenograft (PDX) Models Market Restraints
Figure 64. Patient-derived Xenograft (PDX) Models Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Patient-derived Xenograft (PDX) Models in 2022
Figure 67. Manufacturing Process Analysis of Patient-derived Xenograft (PDX) Models
Figure 68. Patient-derived Xenograft (PDX) Models Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source